SSSameh Shamaa

Sameh Shamaa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sameh Shamaa has a total of 85 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    High prevalence of Hepatitis C Virus associated B-cell lymphoma in Mansoura Region (Egypt), ANRS 12263 study

    by Layla M. Saleh, Danielle Canioni, Sameh Shamaa, Maha El-Zaafarany, Ziad Emarah, Sherin Abdel-Aziz, Entsar Eladle, Alsaeed Abdelaziz, Olivier Hermine, Caroline Besson, et al.

    : Background: The prevalence of Hepatitis C virus in Egypt reaches 15%, which is considered the highest in the world. Genotype 4 represents 93 % of Egyptian HCV infections. Non-Hodgkin lymphoma (NHL) is the 5th most common cancer in Egypt. The association between HCV infection and occurrence of B-cell NHL is well known while data are scarce in Eastern countries. Objectives: We aimed to evaluate the prevalence of HCV infection among patients with B-cell NHL and the clinical characteristics of HCV associated B-cell NHL in Delta region (Mansoura-Egypt). Methods: Between March 2012 and March 2013, 110 adult patients newly diagnosed with B-cell NHL were enrolled in the current study. This study was carried out at Oncology Center, Mansoura University. Study subjects provided serum for HCV testing and for HCV RNA. Results: The prevalence of HCV infection among these patients was 61% (67/110 patients) which is the highest reported value in literature. Among them, 80% (32/40 tested patients) presented with viremia. Contrasting with the histological distribution previously described in Northern regions, the majority of HCV associated lymphomas were DLBCLs (72 %) followed by SLL/CLL (13 %), follicular lymphomas (7.5%) and 7.5% of marginal zone lymphomas. In conclusion: B-cell lymphomas are highly associated with HCV infection in Egypt. Further developments are needed to give access to antiviral treatment for those patients in Delta region.


  • The prognostic significance of breast cancer stem cells in patients with metastatic breast cancer.

    by Kamel Farag, Sameh Sayed Ahmed Shamaa

    E12565 Background: Breast cancer ranks as the first malignancy affecting females.There is increasing evidence that this cancer is originated in and maintained by a small population of undifferentiated cells with self-renewal and proliferation capacities that called breast cancer stem cells (BCSCs). Methods: This study was conducted on 60 patients with metastatic breast cancer, presented to outpatient clinics in Oncology Center, Mansoura University from December 2010 till November 2014. All patients received treatment according to protocols and guidelines. The presence of breast cancer Stem cells was evaluated by immunohistochemistry expression of CD44 and CD24 to assess its possible prognostic and predictive values via correlation with overall survival, tumor response and different clinico-pathological features of the patients. The expression patterns were analyzed according to the clinico-pathologic prognostic parameters as well as overall survival. Results: Median age was 50 (31-70) years. Twenty six patients (43.3%) were premenopausal and 34 patients (56.7%) were postmenopausal. This study classified the breast tumor tissues into four subgroups according to CD44 and CD24 expression patterns (CD44+ CD24- group that carry stem cell property were 41.7% and the remaining three groups ( CD44- CD24-, CD44+ CD24+ , CD44- CD24+) were 58.3%. 64% of tumors with CD44+ CD24- BCSCs were IDC histology, 84% of cases belongs to this group were grade 3, 88% were stage III on presentation, 56% were luminal subtype, 68% of them developed both bone and visceral metastasis. Our study showed that presence of BCSCs (CD44+ CD24-) carry significantly shorter OS (19 vs. 44 months) compared to other three groups. Also, a multivariate analysis, showed that presence of BCSCs (CD44+ CD24-) was significant independent prognostic factor for poor overall survival. Conclusions: This study is a prospective trial testing the concept of detecting breast cancer stem cells in tumor tissue biopsies, according to CD44 & CD24 expression status. As such, it has demonstrated both the feasibility of this approach and its implication as a future prognostic marker, and has paved the way for future research in this field.

  • Open Access

    Inter-Observer Agreement of Whole-Body Computed Tomography in Staging and Response Assessment in Lymphoma: The Lugano Classification

    by Ahmed Abdel Khalek Abdel Razek, Sameh Shamaa, Mahmoud Abdel Lattif, Hanan Hamid Yousef

    Background: to assess inter-observer agreement of whole-body computed tomography (WBCT) in staging and response assessment in lymphoma according to the Lugano classification. Material/Methods: Retrospective analysis was conducted of 115 consecutive patients with lymphomas (45 females, 70 males; mean age of 46 years). Patients underwent WBCT with a 64 multi-detector CT device for staging and response assessment after a complete course of chemotherapy. Image analysis was performed by 2 reviewers according to the Lugano classification for staging and response assessment. Results: The overall inter-observer agreement of WBCT in staging of lymphoma was excellent (k=0.90, percent agreement=94.9%). There was an excellent inter-observer agreement for stage I (k=0.93, percent agreement=96.4%), stage II (k=0.90, percent agreement=94.8%), stage III (k=0.89, percent agreement=94.6%) and stage IV (k=0.88, percent agreement=94%). The overall inter-observer agreement in response assessment after a completer course of treatment was excellent (k=0.91, percent agreement=95.8%). There was an excellent inter-observer agreement in progressive disease (k=0.94, percent agreement=97.1%), stable disease (k=0.90, percent agreement=95%), partial response (k=0.96, percent agreement=98.1%) and complete response (k=0.87, Percent agreement=93.3%). Conclusions: We concluded that WBCT is a reliable and reproducible imaging modality for staging and treatment assessment in lymphoma according to the Lugano classification.


  • Open Access

    Computed Tomography Assessment of Hepatic Metastases of Breast Cancer with Revised Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Version 1.1): Inter-Observer Agreement

    by Fady Emil Ibrahim Ghobrial, Manal Salah Eldin, Ahmed Abdel Khalek Abdel Razek, Nadia Ibrahim Atwan, Sameh Sayed Ahmed Shamaa

    Background: To assess inter-observer agreement of revised RECIST criteria (version 1.1) for computed tomography assessment of hepatic metastases of breast cancer. Material/Methods: A prospective study was conducted in 28 female patients with breast cancer and with at least one measurable metastatic lesion in the liver that was treated with 3 cycles of anthracycline-based chemotherapy. All patients underwent computed tomography of the abdomen with 64-row multi- detector CT at baseline and after 3 cycles of chemotherapy for response assessment. Image analysis was performed by 2 observers, based on the RECIST criteria (version 1.1). Results: Computed tomography revealed partial response of hepatic metastases in 7 patients (25%) by one observer and in 10 patients (35.7%) by the other observer, with good inter-observer agreement (k=0.75, percent agreement of 89.29%). Stable disease was detected in 19 patients (67.8%) by one observer and in 16 patients (57.1%) by the other observer, with good agreement (k=0.774, percent agreement of 89.29%). Progressive disease was detected in 2 patients (7.2%) by both observers, with perfect agreement (k=1, percent agreement of 100%). The overall inter-observer agreement in the CT-based response assessment of hepatic metastasis between the two observers was good (k=0.793, percent agreement of 89.29%). Conclusions: We concluded that computed tomography is a reliable and reproducible imaging modality for response assessment of hepatic metastases of breast cancer according to the RECIST criteria (version 1.1).


  • Open Access

    Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report and Clinicopathological Review

    by Marwa Mohammed Abdel Fattah Zaki, Khaled Zalata, Amira Kamal El-Hawary, Noha Eisa, Shaimaa El Ashwah, Sameh Shamaa

    Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is aggressive hematopoietic malignancy derived from the precursors of plasmacytoid dendritic cells. The present study reported a case of a 35-year-old BPDCN patient, who presented with scalp lesions without extracutaneous involvement of the lymph nodes (LNs), peripheral or bone marrow. Histopathological examination of scalp lesion revealed monomorphous diffuse infiltrate of small to medium-sized cells with irregular nuclear contours, pleomorphic nuclei, finely dispersed chromatin, inconspicuous nucleoli and scant amount of cytoplasm. Immunohistochemical staining showed diffuse positivity for CD45, CD4, CD 56, CD45 and negative for CD3, CD5, CD7, CD8, CD19, CD20, CD30, CD33, CD34, CD79a, CD99, CD117, TDT, and myeloperoxidase. Patient started treatment with acute lymphoblastic lymphoma protocol (Hyper-CVAD). Reevaluation after the second course showed marked regression of scalp lesion. The patient continued Hyper-CVAD protocol and planned for allogeneic stem cell transplant. J Hematol. 2018;7(3):124-127 doi: https://doi.org/10.14740/jh428w

  • Open Access

    A Metastatic Signet Ring Cell Carcinoma Presented as Acquired Thrombotic Thrombocytopenic Purpura: A Case Report

    by Noha Eisa, Khalid Nasef, Ziad Emarah, Marwa Mohamed Abdel Fattah, Sameh Shamaa

    A Metastatic Signet Ring Cell Carcinoma Presented as Acquired Thrombotic Thrombocytopenic Purpura: A Case Report


  • Open Access

    Prognostic Utility of Angiogenic Growth Factors; Basic FGF, VEGF and PDGF-bb in Patients with Lymphoma

    by Osama Elbaz, Hasan A. Abdel-Ghaf, Shaker A. Mousa, Sameh S. Shamaa, Ahmed H. El-Sebaie


  • Phase II study of low-dose fixed-rate infusion of gemcitabine combined with cisplatin and dexamethasone in resistant non-Hodgkin lymphoma and correlation with Bcl-2 and MDR expression

    by Shereef Elsamany, Mian U. Farooq, Mostafa Elsirafy, Sameh Shamaa, Mona Sakr

    This study aims to assess the efficacy of low-dose fixed-rate infusion of gemcitabine, cisplatin and dexamethasone in resistant non-Hodgkin lymphoma (NHL) patients in addition to evaluating the prognostic value of B cell lymphoma 2 (Bcl-2) and multidrug resistant (MDR) expression in this cohort of patients. Patients with relapsed/refractory NHL following at least two chemotherapy regimens were enrolled. They received gemcitabine 800 mg/m2 in fixed infusion rate of 10 mg/m2/min, cisplatin 35 mg/m2 in days 1, 15 and dexamethasone 20 mg days 1–4, 15–18 every 28 day. Response to treatment, time to disease progression (TTP) and 1-year progression-free survival (PFS) were assessed together with their association with Bcl-2, MDR expression and other prognostic variables. Overall response to treatment was 32 % (14 % complete response). Median TTP and 1-year PFS were 2 months and 31.3 %, respectively. Predictors of response to treatment were early stage [odd ratio (OR) = 4.6, 95 % CI 1.3–16.4], low/low intermediate International Prognostic Index (IPI) (OR = 6.2, 95 % CI 1.2–31.7), negative/low Bcl-2 expression (OR = 6.2, 95 % CI 1.2–31.7) and negative/low MDR expression (OR = 18, 95 % CI 1.4–28.9). However, IPI status lost its value in multivariate analysis. TTP and 1-year PFS were significantly associated with Bcl-2 expression (p = 0.04), tumor status before enrollment (relapse vs. refractory, p < 0.0001) and tumor stage (p < 0.000). In multivariate analysis, clinical stage was the only predictor of TTP and 1-year PFS. Fixed-rate gemcitabine infusion with cisplatin and dexamethasone had reasonable activity in resistant NHL. Clinical stage, Bcl-2 and MDR expressions were predictors of response to treatment, while only clinical stage was associated with TTP and 1-year PFS.


  • Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: a randomized phase II trial—an update

    by Rasha Haggag, Kamel Farag, Fouad Abu-Taleb, Sameh Shamaa, Abdel-Rahman Zekri, Tarek Elbolkainy, Hussein Khaled

    Prolonged infusion of low-dose gemcitabine and cisplatin (GC) proved to be an effective treatment for patients with advanced bladder cancer. One hundred and twenty untreated patients with stage III/IV bladder cancer were randomized to receive either gemcitabine (250 mg/m2) 6-h infusion on days 1 and 8, and cisplatin (70 mg/m2) on day 2 every 21-day cycle (arm 1) or gemcitabine (1,250 mg/m2) 30-min infusion on days 1 and 8, with the same dose of cisplatin (arm 2). The 92 males and 28 females included in the study had a median age of 62 years (range 40–85 years). Among the 120 patient, complete response was achieved in 11.7 % (7/60 patients of arm 1) and 5 % (3/60 patients of arm 2). Eighteen patients in arm 1 (30 %) and 17 patients (28.3 %) in arm 2 had partial response on therapy. Thus, the overall response rate of patients in arm 1 and arm 2 was 41.7 % (25/60 patients) and 33.3 % (20/60 patients), respectively (p = 0.37). No significant difference in median time to disease progression (26 vs. 24 months, p = 0.4), median survival (12 vs. 16 months, p = 0.8), and 1-year survival (49.9 vs. 54.7 %, p = 0.8) was detected between arms 1 and 2, respectively. Main toxicities were similar in both arms with no statistically significant differences. Low-dose, prolonged infusion gemcitabine in combination with cisplatin is not inferior to the standard GC regimen with favorable toxicity profile and less financial costs.